WHO recommends clinical trials for three experimental treatments for Bundibugyo Ebola strain (straitstimes.com)

• WHO prioritizes MBP134, maftivimab, and remdesivir for clinical trials
• Obeldesivir recommended for post-exposure prophylaxis
• rVSV Bundibugyo vaccine available in 7-9 months; ChAdOx1 in 2-3 months

"On May 28, 2026, the WHO recommended prioritizing three experimental treatments for the Bundibugyo Ebola strain: MBP134, maftivimab, and remdesivir, to be evaluated in clinical trials. No approved vaccines or therapies exist for this strain. Obeldesivir was highlighted for post-exposure prophylaxis. The outbreak is ongoing in the Democratic Republic of the Congo and Uganda."